Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry A Schechter

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Clinical Ophthalmology (Auckland, N.Z.)|January 20, 2021
Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis SiccaJohn Sheppard, Mark Bergmann, Barry A Schechter, et al.
American Journal of Ophthalmology|July 26, 2002
Treatment of conjunctival papillomata with topical interferon Alfa-2bBarry A Schechter, William J Rand, Gabriel E Velazquez, et al.
Cornea|January 24, 2002
Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2bBarry A Schechter, Amilia Schrier, Robert S Nagler, et al.
Ophthalmology and Therapy|November 17, 2019
An Evaluation of Staphylococci from Ocular Surface Infections Treated Empirically with Topical Besifloxacin: Antibiotic Resistance, Molecular Characteristics, and Clinical OutcomesBarry A Schechter, John D Sheppard, Christine M Sanfilippo, et al.
Clinical Ophthalmology (Auckland, N.Z.)|December 20, 2022
Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical TrialBarry A Schechter, Maitee Urbieta, Jason Bacharach, et al.
Ophthalmology|April 10, 2019
A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye DiseaseDamien F Goldberg, Ranjan P Malhotra, Barry A Schechter, et al.
Clinical Ophthalmology (Auckland, N.Z.)|October 17, 2018
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye diseaseJoseph Tauber, Barry A Schechter, Jason Bacharach, et al.
Cornea|December 18, 2004
Corneal melt after amniotic membrane transplantBarry A Schechter, William J Rand, Robert S Nagler, et al.
Cornea|July 16, 2019
Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 StudiesRanjan Malhotra, Douglas K Devries, Jodi Luchs, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|August 3, 2019
Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Conjunctival Staining in Patients with Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and 3 Clinical TrialsRobert Smyth-Medina, Josh Johnston, Douglas K Devries, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Clinical Ophthalmology (Auckland, N.Z.)|January 20, 2021
Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis SiccaJohn Sheppard, Mark Bergmann, Barry A Schechter, et al.
American Journal of Ophthalmology|July 26, 2002
Treatment of conjunctival papillomata with topical interferon Alfa-2bBarry A Schechter, William J Rand, Gabriel E Velazquez, et al.
Cornea|January 24, 2002
Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2bBarry A Schechter, Amilia Schrier, Robert S Nagler, et al.
Ophthalmology and Therapy|November 17, 2019
An Evaluation of Staphylococci from Ocular Surface Infections Treated Empirically with Topical Besifloxacin: Antibiotic Resistance, Molecular Characteristics, and Clinical OutcomesBarry A Schechter, John D Sheppard, Christine M Sanfilippo, et al.
Clinical Ophthalmology (Auckland, N.Z.)|December 20, 2022
Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical TrialBarry A Schechter, Maitee Urbieta, Jason Bacharach, et al.
Ophthalmology|April 10, 2019
A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye DiseaseDamien F Goldberg, Ranjan P Malhotra, Barry A Schechter, et al.
Clinical Ophthalmology (Auckland, N.Z.)|October 17, 2018
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye diseaseJoseph Tauber, Barry A Schechter, Jason Bacharach, et al.
Cornea|December 18, 2004
Corneal melt after amniotic membrane transplantBarry A Schechter, William J Rand, Robert S Nagler, et al.
Cornea|July 16, 2019
Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 StudiesRanjan Malhotra, Douglas K Devries, Jodi Luchs, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|August 3, 2019
Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Conjunctival Staining in Patients with Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and 3 Clinical TrialsRobert Smyth-Medina, Josh Johnston, Douglas K Devries, et al.
Pageof 2